|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling显示文摘The stromal compartment of the tumor microenvironment consists of a heterogeneous set of tissue-resident and tumor-infiltrating cells,which are profoundly moulded by cancer cells.An outstanding question is to what extent this heterogeneity is similar between cancers affecting different organs.Here,we profile 233,591 single cells from patients with lung,colorectal,ovary and breast cancer(n=36)and construct a pan-cancer blueprint of stromal cell heterogeneity using different single-cell RNA and protein-based technologies.We identify 68 stromal cell populations,of which 46 are shared between cancer types and 22 are unique.We also characterise each population phenotypically by highlighting its marker genes,transcription factors,metabolic activities and tissue-specific expression differences.Resident cell types are characterised by substantial tissue specificity,while tumor-infiltrating cell types are largely shared across cancer types.Finally,by applying the blueprint to melanoma tumors treated with checkpoint immunotherapy and identifying a naive CD4+T-cell phenotype predictive of response to checkpoint immunotherapy,we illustrate how it can serve as a guide to interpret scRNA-seq data.In conclusion,by providing a comprehensive blueprint through an interactive web server,we generate the first panoramic view on the shared complexity of stromal cells in different cancers. | Junbin Qian Siel Olbrecht Bram Boeckx Hanne Vos Damya Laoui Emre Etlioglu Els Wauters Valentina Pomella Sara Verbandt Pieter Busschaert Ayse Bassez Amelie Franken Marlies Vanden Bempt Jieyi Xiong Birgit Weynand Yannick van Herck Asier Antoranz Francesca Maria Bosisio Bernard Thienpont Giuseppe Floris Ignace Vergote Ann Smeets Sabine Tejpar Diether Lambrechts | 2020 | Cell Research2020，30，9： | 11 |
| 2 | Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson’s disease显示文摘To date there is no treatment able to stop or slow down the loss of dopaminergic neurons that characterizes Parkinson’s disease.It was recently observed in a rodent model of Alzheimer’s disease that the interaction between the α7 subtype of nicotinic acetylcholine receptor(α7-nAChR)and sigma-1 receptor(σ1-R)could exert neuroprotective effects through the modulation of neuroinflammation which is one of the key components of the pathophysiology of Parkinson’s disease.In this context,the aim of the present study was to assess the effects of the concomitant administration of N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-furo[2,3-c]pyridine-5-carboxamide(PHA)543613 as an α7-nAChR agonist and 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate(PRE)-084 as aσ1-R agonist in a well-characterized 6-hydroxydopamine rat model of Parkinson’s disease.The animals received either vehicle separately or the dual therapy PHA/PRE once a day until day 14 postlesion.Although no effect was noticed in the amphetamine-induced rotation test,our data has shown that the PHA/PRE treatment induced partial protection of the dopaminergic neurons(15-20%),assessed by the dopamine transporter density in the striatum and immunoreactive tyrosine hydroxylase in the substantia nigra.Furthermore,this dual therapy reduced the degree of glial activation consecutive to the 6-hydroxydopamine lesion,i.e,the 18 kDa translocation protein density and glial fibrillary acidic protein staining in the striatum,and the CD11b and glial fibrillary acidic protein staining in the substantia nigra.Hence,this study reports for the first time that concomitant activation of α7-nAChR andσ1-R can provide a partial recovery of the nigro-striatal dopaminergic neurons through the modulation of microglial activation.The study was approved by the Regional Ethics Committee(CEEA Val de Loire n°19)validated this protocol(Authorization N°00434.02)on May 15,2014. | Steven Vetel Laura Foucault-Fruchard Claire Tronel Frédéric Buron Jackie Vergote Sylvie Bodard Sylvain Routier Sophie Sérrière Sylvie Chalon | 2021 | Neural Regeneration Research2021，16，6： | 3 |
| 3 | Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis ( IOTA ) studies显示文摘 | J. Kaijser T. Bourne L. Valentin A. Sayasneh C. Van Holsbeke I. Vergote A. C. Testa D. Franchi B. Van Calster D. Timmerman | 2012 | Ultrasound Obstet Gynecol2012，，： | 2 |
| 4 | A randomised, double-blind, phase Ⅱ study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer 显示文摘 | Vergote I Calvert H Kania M | 2009 | Eur J Cancer2009，45，8： | 1 |
| 5 | Postmenopausal Women who Progress on Fulvestrant (’Faslodex’) Remain Sensitive to Further Endocrine Therapy显示文摘 | I. Vergote J.F.R. Robertson U. Kleeberg G. Burton C.K. Osborne L. Mauriac | 2003 | Breast Cancer Research and Treatment2003，，2： | 1 |
| 6 | Interval debulking surgery:an alternative for primary surgical debulking? 显示文摘 | Vergote I Wever Tjalma W Van Gramberen M | 2000 | Semin Surg Oncol2000，19，： | 1 |
| 7 | Prognostic importance of degree of differentiation and cyst rupture in stage I invasive ep- ithelial ovarian carcinoma显示文摘 | Vergote I DeBrabanter J Fyles A | 2001 | Lancet2001，357，： | 1 |
| 8 | Timing of debulking surgery in advanced ovarian cancer显示文摘 | I. VERGOTE T. VAN GORP F. AMANT K. LEUNEN P. NEVEN P. BERTELOOT | 2008 | International Journal of Gynecological Cancer2008，，： | 1 |
| 9 | Interval debulking surgery: an alternative for primary surgical debulking显示文摘 | Vergote I De Wever I Tjalma W | 2000 | Semin Surg Oncol2000，19，1： | 1 |
| 10 | Neoadjvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:a retrospective analysis of 285 patients 显示文摘 | Vergote I De Wever I Tjalma W | 1998 | Gynecol Oncol1998，71，3： | 1 |
| 11 | Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian caneer显示文摘 | Vergote IB De Wever I Decloedt J | 2000 | Se- min Oncol2000，27，1： | 1 |
| 12 | Neoadjuvant chemotherapy in advanced ovarian carcinoma: on what do we agree and disagree? 显示文摘 | Vergote I du Bois Av Ament Fv et a1 | 2013 | Gynecol Onco)2013，128，1： | 1 |
| 13 | Neoadjuvantchemotherapy or primary surgery in stageⅢC orⅣovariancancer显示文摘 | Vergote I TropéC G Amant F | 2010 | N Engl J Med2010，363，10： | 1 |
| 14 | Molecular characterization of hepatitis B virus (HBV) strains circulating in the northern coast of the Persian Gulf and its comparison with worldwide distribution of HBV subgenotype D1显示文摘 | Mahmoud Reza Pourkarim Valentijn Vergote Samad Amini‐Bavil‐Olyaee Zohre Sharifi Steven Sijmons Philippe Lemey Piet Maes Seyed Moayed Alavian Marc Van Ranst | 2014 | Virol2014，，5： | 1 |
| 15 | Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer显示文摘 | Vergote I Amant F Kristensen G | 2011 | Eur J Cancer2011，473，： | 1 |
| 16 | Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial显示文摘 | Trimbos JB Vergote I Bolis G | 2003 | J Natl Cancer Inst2003，95，2： | 1 |
| 17 | Wax beads as cushioning agents during the compression of coated diltiazem pellets显示文摘 | VERGOTE GJ KIEKENS F VERVAET C | 2002 | Eur J Pharm Sci2002，17，3： | 1 |
| 18 | Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma 显示文摘 | Vergote I De Brabanter JM Fyles A | 2001 | Lancet2001，357，9251： | 1 |
| 19 | Neoadjuvant chemother apy versus primary debulking surgery in advanced ovarian careino ma显示文摘 | Vergote IB De Wever I DecloedtJ ct al | 2000 | Semin Oncol2000，27，37： | 1 |
| 20 | Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients 显示文摘 | Vergote I De Wever I Tjalma W | 1998 | Gynecol Oncol1998，71，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员